当前位置: 首页 > 期刊 > 《中国现代医生》 > 2019年第9期
编号:13387303
阿替普酶静脉溶栓治疗轻型缺血性卒中的临床研究(5)
http://www.100md.com 2019年3月25日 《中国现代医生》 2019年第9期
     [19] Mishra NK,Lyden P,Grotta JC,et al.Thrombolysis is associated with consistent functional improvement across baseline stroke severity:A comparison of outcomes in patients from the Virtual International Stroke Trials Archive(VISTA)[J].Stroke,2010,41(11):2612-2617.

    [20] Logallo N,Kvistad CE,Naess H,et al. Mild stroke:safety and outcome in patients receiving thrombolysis[J]. Acta Neurol Scand Suppl,2014,(198):37-40.

    [21] 于若梅,曹謖涵,毛保义.重组组织型纤溶酶原激活剂静脉治疗轻型缺血性卒中患者的疗效分析[J].中国卒中杂志,2018,13(9):903-907.

    [22] Khatri P,Tayama D,Cohen G,et al.Effect of intravenous recombinant tissue-type plasminogen activator in patients with mild stroke in the third international stroke trial-3:Post hoc analysis[J].Stroke,2015,46(8):2325-2327.

    [23] Frank B,Grotta JC,Alexandrov AV,et al.Thrombolysis in stroke despite contraindications or warnings?[J].Stroke,2013,44(3):727-733.

    [24] Huisa BN,Raman R,Neil W,et al.Intravenous tissue plasminogen activator for patients with minor ischemic stroke[J].J Stroke Cerebrovasc Dis,2012,21(8):732-736.

    [25] Ahmed N,Wahlgren N,Grond M,et al.Implementation and outcome of thrombolysis with alteplase 3-4.5 h after an acute stroke:An updated analysis from SITS-ISTR[J].Lancet Neurol,2010,9(9):866-874.

    (收稿日期:2018-12-12), http://www.100md.com(王玉才 王会 张梅)
上一页1 2 3 4 5